Bayer to pursue Nexavar patent case in Mumbai High court

Bayer AG, Germany-based pharmaceuticals giant, declared on Monday that it would challenge the Indian Intellectual Property Appellate Board’s decision regarding its anti-cancer drug Nexavar in high court. The Controller General of Patents (CGP) allowed Hyderabad-based Natco to produce and sell a generic version of Bayer’s anti-cancer drug Nexavar. The German pharmaceuticals company opposed the decision and took the matter to India’s Intellectual Property Appellate Board (IPAB), which upheld the CGP’s decision. read more

Bayer AG, Germany-based pharmaceuticals giant, declared on Monday that it would challenge the Indian Intellectual Property Appellate Board’s decision regarding its anti-cancer drug Nexavar in high court. The Controller General of Patents (CGP) allowed Hyderabad-based Natco to produce and sell a generic version of Bayer’s anti-cancer drug Nexavar. The German pharmaceuticals company opposed the decision and took the matter to India’s Intellectual Property Appellate Board (IPAB), which upheld the CGP’s decision. read more

[via Stock Watch – Stock Specific News]

Follow us @enterpriseheat – lists / @sectorheat

Leave a Reply

Your email address will not be published. Required fields are marked *